SIGA is now considered a leading drug development company in the biodefense arena. Its portfolio of existing drug candidates and its platform for developing additional countermeasures against potential agents of biological warfare are intended to fill a critical need for safe and effective treatments. Its lead product, the smallpox therapeutic ST-246^®, has completely prevented mortality in each and every animal efficacy trial and is now undergoing NDA-enabling studies. SIGA’s other antiviral agents against Lassa fever, Junín, Ebola and Marburg are currently undergoing efficacy testing. SIGA is also applying its high-throughput screening technologies to identify the most likely candidates for therapeutic intervention against bunyavirus, Dengue fever, anthrax, and other category A disease threats.